HomeCompareRVXCF vs SBUX

RVXCF vs SBUX: Dividend Comparison 2026

RVXCF yields 2500.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $80609755877.20M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RVXCF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — RVXCF vs SBUX

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, RVXCF beats the other by $63,520,143,069,519,470.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + SBUX for your $10,000?

RVXCF: 50%SBUX: 50%
100% SBUX50/50100% RVXCF
Portfolio after 10yr
$40304877938.77M
Annual income
$37,364,790,040,964,940.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
SBUX buys
0
No recent congressional trades found for RVXCF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFSBUX
Forward yield2500.00%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$80609755877.37M$167.0K
Annual income after 10y$74,729,580,081,858,750.00$71,136.45
Total dividends collected$80198875900.38M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: RVXCF vs SBUX ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$260,700$250,000.00$11,121$420.68+$249.6KRVXCF
2$6,370,070$6,091,121.50$12,548$648.40+$6.36MRVXCF
3$145,912,632$139,096,656.81$14,440$1,013.98+$145.90MRVXCF
4$3,133,830,814$2,977,704,297.75$17,068$1,617.30+$3133.81MRVXCF
5$63,122,812,060$59,769,613,088.96$20,912$2,649.52+$63122.79MRVXCF
6$1,192,683,724,131$1,125,142,315,226.76$26,875$4,499.29+$1192683.70MRVXCF
7$21,144,559,711,004$19,868,388,126,183.19$36,771$8,014.12+$21144559.67MRVXCF
8$351,818,906,448,043$329,194,227,557,269.44$54,542$15,197.11+$351818906.39MRVXCF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$89,602$31,242.49+$5495491397.58MRVXCF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$167,011$71,136.45+$80609755877.20MRVXCF

RVXCF vs SBUX: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this RVXCF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.